Harpoon Therapeutics to Participate in the SVB Securities Global Biopharma Conference
Harpoon Therapeutics, a clinical-stage immuno-oncology company, announced its participation in the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET. The presentation will highlight the company's innovative T cell engagers developed through its proprietary TriTAC platform, aimed at treating cancer and other diseases. A live audio webcast of the presentation will be accessible on Harpoon's website, with an archived version available afterward. For more information about Harpoon's platforms and treatments, visit www.harpoontx.com.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that management will present at the virtual SVB Securities Global Biopharma Conference. The corporate presentation will take place on Tuesday, February 14, 2023 at 1:40 p.m. ET (10:40 a.m. PT).
A live audio webcast of the company presentation will be available in the Investors section of the Harpoon Therapeutics website at www.harpoontx.com with an archived replay available following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon’s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Contacts:
ICR Westwicke:
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
Media:
uncapped Communications
512-825-2603
megan.russell@uncappedcommunications.com
FAQ
What conference will Harpoon Therapeutics be presenting at in February 2023?
What time is the Harpoon Therapeutics presentation scheduled?
How can I access the Harpoon Therapeutics presentation?
What technology platforms does Harpoon Therapeutics utilize?
What is the focus of Harpoon Therapeutics' T cell engagers?
